STRS Ohio’s Aevi Genomic Medicine Inc GNMX Stock Holding History

STRS Ohio’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,200	Closed	-$9K	–	2058
2017 Q1	$9K	Hold	5,200	–	–	﹤0.01%	1857
2016 Q4	$26K	Hold	5,200	–	–	﹤0.01%	1843
2016 Q3	$28K	Sell	5,200 -200	-4%	-$1.14K	﹤0.01%	1821
2016 Q2	$29K	Hold	5,400	–	–	﹤0.01%	1837
2016 Q1	$23K	Hold	5,400	–	–	﹤0.01%	1815
2015 Q4	$32K	Hold	5,400	–	–	﹤0.01%	1821
2015 Q3	$42K	Hold	5,400	–	–	﹤0.01%	1775
2015 Q2	$33K	Buy	+5,400	New	+$41.8K	﹤0.01%	1796

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

STRS Ohio's GNMX Position: Q2 2017 in Review

STRS Ohio sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 5,200 shares — an estimated $9K sold.

STRS Ohio first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $42K in Q3 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

STRS Ohio reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
STRS Ohio sold 5,200 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $9K.
STRS Ohio first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
STRS Ohio's Aevi Genomic Medicine Inc position peaked at $42K in Q3 2015.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on STRS Ohio's 13F filing for Q2 2017, filed 26 Jul 2017.